The WHO Global Status Report on Cancer 2026 points to a central reality of modern cancer care: advances in diagnosis and treatment have improved outcomes for many patients, but access to these advances remains profoundly unequal across countries, regions, and health systems.
How does this reality look through a hematology lens?
Blood Cancers Within the Global Cancer Burden
Hematologic malignancies are a meaningful share of cancers worldwide: leukemia accounts for approximately 2.3% of all cancers in women and 2.9% of all cancers in men. Non-Hodgkin lymphoma represents 2.6% and 3.3% of cancers in women and men, respectively, while multiple myeloma accounts for 0.9% and 1.1%, and Hodgkin lymphoma for 0.4% and 0.5%.
Together, these diseases account for more than 1.3 million new diagnoses worldwide each year and place substantial demands on health systems due to their need for specialized diagnostics, sophisticated therapies, and long-term follow-up.
Childhood Leukemia and the Global Survival Gap
The WHO estimates that approximately 400,000 new cancers occur annually among children and adolescents (0-19 years) worldwide, with nearly 90% arising in low- and middle-income countries. While advances in pediatric oncology have pushed 5-year survival beyond 85% in high-income countries, much of the world has yet to share equally in this progress, with survival remaining below 45% in low-income countries.
Leukemia is the most common childhood cancer worldwide, accounting for approximately one-quarter of all pediatric cancer diagnoses, with acute lymphoblastic leukemia being the largest subtype. Leukemia caused an estimated 34,600 deaths among children and adolescents worldwide in 2024, with the burden concentrated in regions with the largest pediatric populations, particularly Asia and Africa.
Given that cure rates for childhood ALL exceed 80-90% in many specialized treatment centers, much of this mortality reflects differences in access to timely diagnosis, pediatric oncology services, chemotherapy, supportive care, infection management, blood products, and long-term follow-up.
Acute Lymphoblastic Leukemia (ALL) in Adults vs Children: Why Such Differences in Survival
Diagnostic Capacity and Access to Treatment
Access to timely diagnosis is uneven across much of the world. An estimated 47% of the global population has little or no access to basic diagnostic services, contributing to delays in diagnosis and treatment initiation. Limitations in infrastructure, workforce, diagnostic equipment and pathology services shape cancer care in many settings.
The same is evident in access to cancer medicines, with hospital availability ranging from 9-54% in low- and lower-middle-income countries compared with 68-94% in high-income countries. Modern hematology increasingly relies on advanced laboratory testing, specialized pathology services, flow cytometry, cytogenetics, molecular testing, transplant programs, targeted agents and cellular therapies. As these capabilities become integral to hematology practice, disparities in access become more apparent.
Financial Hardship
Only 28% of countries include a minimum cancer management package within their universal health coverage benefit packages, leaving large segments of the global population without guaranteed access to basic cancer services. Even in countries with universal health coverage, indirect costs, including transportation, lost income, caregiving responsibilities, and reduced productivity, can create significant hardship.
For patients with hematologic malignancies, financial burden is increasingly recognized as a clinical issue rather than solely an economic one. A 2026 systematic review and meta-analysis by Liao et al., including more than 280,000 patients, reported an association between financial toxicity and inferior survival.
When Geography Shapes Cancer Risk
The continued concentration of HIV-associated cancers in sub-Saharan Africa reflects a broader reality: the burden of cancer is not distributed evenly, nor are its causes. While many countries face cancers associated with aging populations, others continue to contend with malignancies linked to chronic infections. Recent estimates suggest that approximately 70% of all cancers attributable to HIV worldwide occur in Africa.
HIV-associated non-Hodgkin lymphomas are part of this. The decline in Kaposi sarcoma following the expansion of antiretroviral therapy shows how investments in HIV prevention, diagnosis, and treatment can also serve as investments in cancer control.
Progress in Survival, Gaps in Survivorship
One consequence of therapeutic progress is the growing population of blood cancer survivors. As outcomes improve in diseases such as childhood acute lymphoblastic leukemia, Hodgkin lymphoma, chronic myeloid leukemia, and multiple myeloma, the number of patients requiring long-term follow-up continues to grow.
At the same time, the WHO report identifies significant gaps in survivorship services worldwide. Only 52% of national cancer control plans include strategies addressing post-treatment follow-up care, and access to rehabilitation services remains limited.
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story
Beyond Scientific Progress
Many of the report’s findings are directly relevant to modern blood cancer care and underscore persistent disparities in access to diagnostics, medicines, workforce capacity, financial protection, and survivorship services.
For hematology, these trends coincide with the growing role of advanced diagnostics, molecularly guided therapies, bispecific antibodies, and cellular immunotherapies in routine practice. The report therefore raises a broader question: can access to innovation keep pace with the pace of innovation itself?